Get the Stockscreener App
12.81
0.31%
0.04
After Hours:
12.81
Ocular Therapeutix Inc stock is traded at $12.81, with a volume of 1.84M.
It is up +0.31% in the last 24 hours and up +2.69% over the past month.
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.
See More
Previous Close:
$12.77
Open:
$12.74
24h Volume:
1.84M
Relative Volume:
0.76
Market Cap:
$2.23B
Revenue:
$61.10M
Net Income/Loss:
$-138.36M
P/E Ratio:
-9.4889
EPS:
-1.35
Net Cash Flow:
$-90.59M
1W Performance:
-5.81%
1M Performance:
+2.69%
6M Performance:
+51.96%
1Y Performance:
+47.07%
1-Day Range:
$12.66
$12.91
1-Week Range:
$12.58
$13.65
52-Week Range:
$5.80
$13.85
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Name
Ocular Therapeutix Inc
Sector
Industry
Phone
781-357-4000
Address
15 CROSBY DRIVE, BEDFORD, MA
Compare OCUL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
12.81 | 2.27B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
394.53 | 99.62B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.89 | 61.52B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.00 | 58.91B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
756.38 | 46.69B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
324.34 | 34.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-08-25 | Initiated | William Blair | Outperform |
| Mar-18-25 | Initiated | RBC Capital Mkts | Outperform |
| Mar-11-25 | Initiated | Needham | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jun-20-24 | Upgrade | TD Cowen | Hold → Buy |
| May-31-24 | Resumed | Piper Sandler | Overweight |
| Feb-09-24 | Initiated | BofA Securities | Buy |
| Apr-21-23 | Initiated | Robert W. Baird | Outperform |
| Aug-10-22 | Resumed | Berenberg | Buy |
| Aug-10-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Dec-28-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Nov-13-20 | Reiterated | Raymond James | Strong Buy |
| Aug-10-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-03-20 | Upgrade | Raymond James | Outperform → Strong Buy |
| May-21-19 | Downgrade | Cowen | Outperform → Market Perform |
| May-21-19 | Reiterated | H.C. Wainwright | Buy |
| May-21-19 | Downgrade | Raymond James | Strong Buy → Outperform |
| Dec-03-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-18 | Initiated | Raymond James | Strong Buy |
| Sep-07-18 | Initiated | Piper Jaffray | Overweight |
| Oct-24-17 | Initiated | Guggenheim | Buy |
| Jul-26-17 | Initiated | H.C. Wainwright | Buy |
| Jul-12-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Jun-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-10-17 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | RBC Capital Mkts | Outperform |
| Aug-11-16 | Initiated | JMP Securities | Mkt Outperform |
| Feb-17-16 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-23-15 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-13-15 | Initiated | Morgan Stanley | Overweight |
View All
Ocular Therapeutix Inc Stock (OCUL) Latest News
137,871 Shares in Ocular Therapeutix, Inc. $OCUL Purchased by Cubist Systematic Strategies LLC - MarketBeat
Polar Asset Management Partners Inc. Lowers Stock Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Northern Trust Corp Lowers Stake in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix's (OCUL) Investor Day to Spotlight AXPAXLI Program's Potential in Retinal Disease Treatment - simplywall.st
Analysts Set Ocular Therapeutix, Inc. (NASDAQ:OCUL) Price Target at $17.20 - MarketBeat
Panagora Asset Management Inc. Trims Stock Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Adage Capital Partners GP L.L.C. Purchases 1,600,000 Shares of Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Hypertension Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Bausch + Lomb, Aerie Pharma, Santen Pharma, AbbVie (Allergan), Nicox, Kowa, Qlaris Bio, Noveome Bio - The Globe and Mail
Ocular Therapeutix gains amid takeover speculation - MSN
Ocular Therapeutix (NASDAQ:OCUL) Reaches New 12-Month HighHere's What Happened - MarketBeat
Ocular Therapeutix at Morgan Stanley Conference: Strategic Clinical Insights By Investing.com - Investing.com Canada
Ocular Therapeutix™ to Host Investor Day on September 30, 2025 | - GuruFocus
Ocular Therapeutix™ to Host Investor Day on September 30, 2025 - GlobeNewswire
Ocular Therapeutix: A High-Stakes Bet On Becoming The New Standard Of Care (NASDAQ:OCUL) - Seeking Alpha
Key deals this week: Ocular Therapeutix, CoreWeave, Air Lease, Cadence and more (AL:NYSE) - Seeking Alpha
Best data tools to analyze Ocular Therapeutix Inc. stockWeekly Market Summary & Target Return Focused Stock Picks - Newser
Is Ocular Therapeutix Inc. a candidate for recovery play2025 Key Lessons & AI Forecasted Entry and Exit Points - Newser
Can Ocular Therapeutix Inc. rally from current levelsEarnings Growth Summary & Growth-Oriented Investment Plans - Newser
Can Ocular Therapeutix Inc. disrupt its industryEarnings Summary Report & Real-Time Buy Zone Alerts - خودرو بانک
Signal strength of Ocular Therapeutix Inc. stock in tech scannersTrade Exit Summary & Weekly High Return Forecasts - Newser
Visual trend scoring systems applied to Ocular Therapeutix Inc.July 2025 Snapshot & Daily Profit Maximizing Tips - Newser
What candlestick patterns are forming on Ocular Therapeutix Inc.Trade Volume Report & Real-Time Buy Zone Alerts - Newser
What to do if you’re stuck in Ocular Therapeutix Inc.2025 Buyback Activity & Long Hold Capital Preservation Tips - Newser
Will Ocular Therapeutix Inc. outperform the market in YEAR2025 Buyback Activity & Real-Time Volume Surge Alerts - خودرو بانک
Ocular Therapeutix Shares Rise on Takeover Speculation - AInvest
Ocular Therapeutix gains amid takeover speculation (update) (OCUL:NASDAQ) - Seeking Alpha
Is Ocular Therapeutix Inc. stock bottoming outExit Point & Intraday High Probability Setup Alerts - Newser
Has Ocular Therapeutix Inc. found a price floorTrade Risk Assessment & Low Volatility Stock Suggestions - Newser
How to build a dashboard for Ocular Therapeutix Inc. stockBuy Signal & High Conviction Buy Zone Alerts - Newser
Is Ocular Therapeutix Inc. stock forming a triangle pattern2025 Volatility Report & Growth Focused Stock Reports - خودرو بانک
Paradigm Biocapital Advisors LP Takes $9.63 Million Position in Ocular Therapeutix, Inc. $OCUL - MarketBeat
Ocular Therapeutix's Unusual Options Activity: A Closer Look - AInvest
How to build a custom watchlist for Ocular Therapeutix Inc.Rate Hike & Fast Momentum Stock Entry Tips - Newser
Ocular Therapeutix CEO Donald Notman sells 1066 shares at $12.43/share on Sept 2, 2023. - AInvest
Acute Respiratory Distress Syndrome Market Forecast and Company Analysis Report 2025-2033 Featuring Ajanta, Akorn, Alembic, Cipla, Indoco Remedies, J&J, Novartis, Ocular Therapeutix, Sun, Teva - GlobeNewswire
How hedge fund analytics apply to Ocular Therapeutix Inc. stockMarket Activity Summary & Fast Exit/Entry Strategy Plans - Newser
What are Ocular Therapeutix Inc.’s earnings expectationsQuarterly Portfolio Report & Fast Gain Swing Alerts - خودرو بانک
Will Ocular Therapeutix Inc. outperform the marketPortfolio Risk Summary & Accurate Trade Setup Notifications - Newser
Technical analysis overview for Ocular Therapeutix Inc. stockJuly 2025 Closing Moves & Smart Swing Trading Alerts - Newser
Ocular Therapeutix Inc. stock retracement – recovery analysis2025 Fundamental Recap & Verified Short-Term Plans - Newser
Ocular Therapeutix Inc. stock trend outlook and recovery pathPortfolio Risk Summary & Low Drawdown Momentum Trade Ideas - Newser
Backtesting results for Ocular Therapeutix Inc. trading strategiesWeekly Profit Recap & Verified Momentum Watchlists - Newser
Is Ocular Therapeutix Inc. stock poised for growthDollar Strength & Reliable Breakout Forecasts - Newser
Chart based analysis of Ocular Therapeutix Inc. trends2025 Market Overview & Risk Managed Trade Strategies - Newser
How to use a screener to detect Ocular Therapeutix Inc. breakouts2025 Trading Recap & Daily Growth Stock Tips - Newser
Ocular Therapeutix Inc Stock (OCUL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):